Cullinan Therapeutics, Inc. logo CGEM - Cullinan Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $34.75 DETAILS
HIGH: $40.00
LOW: $27.00
MEDIAN: $36.00
CONSENSUS: $34.75
UPSIDE: 132.91%

Stock News

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be.

Oct 19, 2026 03:00 AM • businesswire.com
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the first patient has been dosed in its pivotal Phase 2 study of CLN-049, a novel, investigational FLT3 T cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML).

Oct 08, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could help corroborate its earlier data. Additionally, if CLN-978 becomes viable for more patients with a manageable safety profile, the potential repeat dosing also seems promising for better efficacy.

Sep 29, 2026 03:30 AM • seekingalpha.com
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November  CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline.

Sep 24, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.

Sep 21, 2026 08:00 AM • globenewswire.com
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.

Sep 14, 2026 03:00 AM • globenewswire.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the International.

Sep 13, 2026 03:15 PM • businesswire.com
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.

Aug 26, 2026 01:41 AM • seekingalpha.com
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at

Aug 19, 2026 08:03 AM • businesswire.com
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML).

Jul 28, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGFR exon 20 insertion NSCLC. Zipalertinib demonstrates promising efficacy, including CNS activity and responses post-amivantamab, with pivotal phase 3 REZILIENT3 data expected later this year. CGEM's diversified pipeline in oncology and immunology, strong cash reserves, and operational runway into 2029 support continued optimism.

Jun 11, 2026 07:41 AM • seekingalpha.com

Price Targets